Combination therapy

Delve into the world of Combination therapy in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Combination therapy to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met
CompanyDrug

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

Betta Pharmaceuticals (SHE: 300558) announced that its partner EyePoint Pharmaceuticals (NASDAQ: EYPT) disclosed data from LUCIA, the second pivotal Phase III clinical trial evaluating EYP‑1901 (DURAVYU), an investigational vorolanib ophthalmic…

Eli Lilly's Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Eli Lilly’s Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Insilico Medicine Earns Milestone Payment from Servier – First Oncology Program Hits Early‑Stage Drug Discovery Mark on Pharma.AI Platform

Insilico Medicine Earns Milestone Payment from Servier – First Oncology Program Hits Early‑Stage Drug Discovery Mark on Pharma.AI Platform

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Evopoint Biosciences Partners with Merck for Phase Ib/II Study Combining XNW5004 and Keytruda

CompanyDrug

OncoSec Medical’s TAVO-EP Combo Misses Primary Endpoint in Melanoma Trial

CompanyDeals

BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda

CompanyDeals

Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies

CompanyDeals

Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors

CompanyDrug

RemeGen Gains NMPA Approval for Phase I/IIa Study of RC88 with Junshi Bio’s PD-1 Inhibitor

CompanyDrug

ImmuneOnco Gains NMPA Approval for Phase Ib/II Study of IMM27M in Advanced Tumors

CompanyDeals

Akeso Biopharma and Shanghai Pharmaceuticals Collaborate on Liposarcoma Treatment

Show More